A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

This study is testing pembrolizumab (an immunotherapy drug) in combination with chemotherapy for people with head and neck cancer that has returned after prior treatment or spread to other parts of the body. Pembrolizumab works by helping the immune system recognize and attack cancer cells. **You may be eligible if...** - You have head and neck cancer that is recurrent (came back) or metastatic (spread to other areas) - You have not previously received systemic treatment (chemotherapy or immunotherapy) for recurrent or metastatic disease - Your cancer has been confirmed by biopsy - You are in adequate health to tolerate chemotherapy and immunotherapy **You may NOT be eligible if...** - You have already received systemic treatment for recurrent or metastatic head and neck cancer - You have active autoimmune disease - You have had serious side effects from prior immunotherapy - You are pregnant or breastfeeding - You have uncontrolled infections or significant organ problems Talk to your doctor to see if this trial is right for you.